{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T12:04:48Z","timestamp":1795176288681,"version":"4.10.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["NRF-2022M3A9G8082662"],"award-info":[{"award-number":["NRF-2022M3A9G8082662"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Health & Welfare, South Korea","award":["HS21C0096"],"award-info":[{"award-number":["HS21C0096"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Gastroesophageal reflux disease (GERD) has been suggested as a risk factor for acute exacerbation of chronic obstructive pulmonary disease (COPD). However, it remains undetermined whether proton pump inhibitor (PPI) treatment reduces the risk of exacerbation or affects the risk of pneumonia. This study aimed to evaluate the risks of both exacerbation and pneumonia following PPI treatment for GERD in patients with COPD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study used a reimbursement database of the Republic of Korea. Patients aged\u2009\u2265\u200940\u00a0years with COPD as a main diagnosis and who received PPI treatment for GERD at least for 14 consecutive days between January 2013 and December 2018 were included in the study. A self-controlled case series analysis was conducted to calculate the risk of moderate and severe exacerbation and pneumonia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 104,439 patients with prevalent COPD received PPI treatment for GERD. The risk of moderate exacerbation was significantly lower during the PPI treatment than at baseline. The risk of severe exacerbation increased during the PPI treatment but significantly decreased in the post-treatment period. Pneumonia risk was not significantly increased during the PPI treatment. The results were similar in patients with incident COPD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The risk of exacerbation was significantly reduced after PPI treatment compared with the non-treated period. Severe exacerbation may increase due to uncontrolled GERD but subsequently decrease following PPI treatment. There was no evidence of an increased risk of pneumonia.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12931-023-02345-1","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T20:24:10Z","timestamp":1679862250000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Effects of gastroesophageal reflux disease treatment with proton pump inhibitors on the risk of acute exacerbation and pneumonia in patients with COPD"],"prefix":"10.1186","volume":"24","author":[{"given":"Jieun","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rugyeom","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sei Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,11]]},"reference":[{"key":"2345_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/resp.12660","volume":"21","author":"JL L\u00f3pez-Campos","year":"2016","unstructured":"L\u00f3pez-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21:14\u201323.","journal-title":"Respirology"},{"key":"2345_CR2","unstructured":"Global strategy for prevention, diagnosis and management of COPD. https:\/\/goldcopd.org\/2021-gold-reports\/."},{"key":"2345_CR3","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1183\/09031936.04.00107004","volume":"23","author":"C Casanova","year":"2004","unstructured":"Casanova C, Baudet JS, del Valle VM, Martin JM, Aguirre-Jaime A, de Torres JP, Celli BR. Increased gastro-oesophageal reflux disease in patients with severe COPD. Eur Respir J. 2004;23:841\u20135.","journal-title":"Eur Respir J"},{"key":"2345_CR4","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1378\/chest.08-0902","volume":"134","author":"LA Garc\u00eda Rodr\u00edguez","year":"2008","unstructured":"Garc\u00eda Rodr\u00edguez LA, Ruig\u00f3mez A, Mart\u00edn-Merino E, Johansson S, Wallander MA. Relationship between gastroesophageal reflux disease and COPD in UK primary care. Chest. 2008;134:1223\u201330.","journal-title":"Chest"},{"key":"2345_CR5","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1378\/chest.119.4.1043","volume":"119","author":"B Mokhlesi","year":"2001","unstructured":"Mokhlesi B, Morris AL, Huang CF, Curcio AJ, Barrett TA, Kamp DW. Increased prevalence of gastroesophageal reflux symptoms in patients with COPD. Chest. 2001;119:1043\u20138.","journal-title":"Chest"},{"key":"2345_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.gtc.2013.11.002","volume":"43","author":"DS Estores","year":"2014","unstructured":"Estores DS. Symptom predictability in gastroesophageal reflux disease and role of proton pump inhibitor test. Gastroenterol Clin North Am. 2014;43:27\u201338.","journal-title":"Gastroenterol Clin North Am"},{"key":"2345_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/resp.12420","volume":"20","author":"TS Ingebrigtsen","year":"2015","unstructured":"Ingebrigtsen TS, Marott JL, Vestbo J, Nordestgaard BG, Hallas J, Lange P. Gastro-esophageal reflux disease and exacerbations in chronic obstructive pulmonary disease. Respirology. 2015;20:101\u20137.","journal-title":"Respirology"},{"key":"2345_CR8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1465-9921-15-62","volume":"15","author":"CH Martinez","year":"2014","unstructured":"Martinez CH, Okajima Y, Murray S, Washko GR, Martinez FJ, Silverman EK, Lee JH, Regan EA, Crapo JD, Curtis JL, et al. Impact of self-reported gastroesophageal reflux disease in subjects from COPDGene cohort. Respir Res. 2014;15:62.","journal-title":"Respir Res"},{"key":"2345_CR9","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1378\/chest.130.4.1096","volume":"130","author":"IE Rascon-Aguilar","year":"2006","unstructured":"Rascon-Aguilar IE, Pamer M, Wludyka P, Cury J, Coultas D, Lambiase LR, Nahman NS, Vega KJ. Role of gastroesophageal reflux symptoms in exacerbations of COPD. Chest. 2006;130:1096\u2013101.","journal-title":"Chest"},{"key":"2345_CR10","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1136\/thx.2007.092858","volume":"63","author":"K Terada","year":"2008","unstructured":"Terada K, Muro S, Sato S, Ohara T, Haruna A, Marumo S, Kinose D, Ogawa E, Hoshino Y, Niimi A, et al. Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation. Thorax. 2008;63:951\u20135.","journal-title":"Thorax"},{"key":"2345_CR11","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.rmed.2015.06.009","volume":"109","author":"VS Benson","year":"2015","unstructured":"Benson VS, M\u00fcllerov\u00e1 H, Vestbo J, Wedzicha JA, Patel A, Hurst JR. Associations between gastro-oesophageal reflux, its management and exacerbations of chronic obstructive pulmonary disease. Respir Med. 2015;109:1147\u201354.","journal-title":"Respir Med"},{"key":"2345_CR12","first-page":"253","volume":"19","author":"M Rogha","year":"2010","unstructured":"Rogha M, Behravesh B, Pourmoghaddas Z. Association of gastroesophageal reflux disease symptoms with exacerbations of chronic obstructive pulmonary disease. J Gastrointest Liver Dis. 2010;19:253\u20136.","journal-title":"J Gastrointest Liver Dis"},{"key":"2345_CR13","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12890-019-1027-z","volume":"20","author":"C Huang","year":"2020","unstructured":"Huang C, Liu Y, Shi G. A systematic review with meta-analysis of gastroesophageal reflux disease and exacerbations of chronic obstructive pulmonary disease. BMC Pulm Med. 2020;20:2.","journal-title":"BMC Pulm Med"},{"key":"2345_CR14","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/j.rmed.2011.03.009","volume":"105","author":"K Takada","year":"2011","unstructured":"Takada K, Matsumoto S, Kojima E, Iwata S, Okachi S, Ninomiya K, Morioka H, Tanaka K, Enomoto Y. Prospective evaluation of the relationship between acute exacerbations of COPD and gastroesophageal reflux disease diagnosed by questionnaire. Respir Med. 2011;105:1531\u20136.","journal-title":"Respir Med"},{"key":"2345_CR15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/000313481808400122","volume":"84","author":"AM Bigatao","year":"2018","unstructured":"Bigatao AM, Herbella FAM, Del Grande LM, Nascimento OA, Jardim JR, Patti MG. Chronic obstructive pulmonary disease exacerbations are influenced by gastroesophageal reflux disease. Am Surg. 2018;84:51\u20135.","journal-title":"Am Surg"},{"key":"2345_CR16","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.2147\/COPD.S157761","volume":"13","author":"VY Su","year":"2018","unstructured":"Su VY, Liao HF, Perng DW, Chou YC, Hsu CC, Chou CL, Chang YL, Yen JC, Chen TJ, Chou TC. Proton pump inhibitors use is associated with a lower risk of acute exacerbation and mortality in patients with coexistent COPD and GERD. Int J Chron Obstruct Pulmon Dis. 2018;13:2907\u201315.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2345_CR17","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/resp.12758","volume":"21","author":"L Baumeler","year":"2016","unstructured":"Baumeler L, Papakonstantinou E, Milenkovic B, Lacoma A, Louis R, Aerts JG, Welte T, Kostikas K, Blasi F, Boersma W, et al. Therapy with proton-pump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD. Respirology. 2016;21:883\u201390.","journal-title":"Respirology"},{"key":"2345_CR18","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1111\/j.1532-5415.2009.02349.x","volume":"57","author":"T Sasaki","year":"2009","unstructured":"Sasaki T, Nakayama K, Yasuda H, Yoshida M, Asamura T, Ohrui T, Arai H, Araya J, Kuwano K, Yamaya M. A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. J Am Geriatr Soc. 2009;57:1453\u20137.","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"2345_CR19","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1177\/10600280211039240","volume":"56","author":"X Xun","year":"2021","unstructured":"Xun X, Yin Q, Fu Y, He X, Dong Z. Proton pump inhibitors and the risk of community-acquired pneumonia: an updated meta-analysis. Ann Pharmacother. 2021;56(5):524\u201332.","journal-title":"Ann Pharmacother"},{"key":"2345_CR20","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1001\/jama.292.16.1955","volume":"292","author":"RJ Laheij","year":"2004","unstructured":"Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292:1955\u201360.","journal-title":"JAMA"},{"key":"2345_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.7326\/0003-4819-149-6-200809160-00005","volume":"149","author":"M Sarkar","year":"2008","unstructured":"Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008;149:391\u20138.","journal-title":"Ann Intern Med"},{"key":"2345_CR22","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/1471-2288-13-82","volume":"13","author":"EN Ramsay","year":"2013","unstructured":"Ramsay EN, Pratt NL, Ryan P, Roughead EE. Proton pump inhibitors and the risk of pneumonia: a comparison of cohort and self-controlled case series designs. BMC Med Res Methodol. 2013;13:82.","journal-title":"BMC Med Res Methodol"},{"key":"2345_CR23","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1001\/archinte.167.9.950","volume":"167","author":"SE Gulmez","year":"2007","unstructured":"Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med. 2007;167:950\u20135.","journal-title":"Arch Intern Med"},{"key":"2345_CR24","doi-asserted-by":"publisher","first-page":"182","DOI":"10.5056\/jnm18001","volume":"24","author":"Y Kinoshita","year":"2018","unstructured":"Kinoshita Y, Ishimura N, Ishihara S. Advantages and disadvantages of long-term proton pump inhibitor use. J Neurogastroenterol Motil. 2018;24:182\u201396.","journal-title":"J Neurogastroenterol Motil"},{"key":"2345_CR25","first-page":"43","volume":"52","author":"J Zielinski","year":"1997","unstructured":"Zielinski J, MacNee W, Wedzicha J, Ambrosino N, Braghiroli A, Dolensky J, Howard P, Gorzelak K, Lahdensuo A, Strom K, et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch Chest Dis. 1997;52:43\u20137.","journal-title":"Monaldi Arch Chest Dis"},{"key":"2345_CR26","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","volume":"363","author":"JR Hurst","year":"2010","unstructured":"Hurst JR, Vestbo J, Anzueto A, Locantore N, M\u00fcllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128\u201338.","journal-title":"N Engl J Med"},{"key":"2345_CR27","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1136\/thorax.58.12.1092","volume":"58","author":"GA Fontana","year":"2003","unstructured":"Fontana GA, Pistolesi M. Cough. 3: chronic cough and gastro-oesophageal reflux. Thorax. 2003;58:1092\u20135.","journal-title":"Thorax"},{"key":"2345_CR28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.arbres.2011.02.001","volume":"47","author":"A Pacheco-Galv\u00e1n","year":"2011","unstructured":"Pacheco-Galv\u00e1n A, Hart SP, Morice AH. Relationship between gastro-oesophageal reflux and airway diseases: the airway reflux paradigm. Arch Bronconeumol. 2011;47:195\u2013203.","journal-title":"Arch Bronconeumol"},{"key":"2345_CR29","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1001\/jama.2009.722","volume":"301","author":"SJ Herzig","year":"2009","unstructured":"Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009;301:2120\u20138.","journal-title":"JAMA"},{"key":"2345_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4292\/wjgpt.v2.i3.17","volume":"2","author":"AL Fohl","year":"2011","unstructured":"Fohl AL, Regal RE. Proton pump inhibitor-associated pneumonia: not a breath of fresh air after all? World J Gastrointest Pharmacol Ther. 2011;2:17\u201326.","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"2345_CR31","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4103\/1735-1995.156174","volume":"20","author":"SW Lee","year":"2015","unstructured":"Lee SW, Lien HC, Chang CS, Yeh HZ, Lee TY, Tung CF. The impact of acid-suppressing drugs to the patients with chronic obstructive pulmonary disease: a nationwide, population-based, cohort study. J Res Med Sci. 2015;20:263\u20137.","journal-title":"J Res Med Sci"},{"key":"2345_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i5813","volume":"355","author":"F Othman","year":"2016","unstructured":"Othman F, Crooks CJ, Card TR. Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study. BMJ. 2016;355: i5813.","journal-title":"BMJ"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02345-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-023-02345-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02345-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,9]],"date-time":"2023-12-09T16:52:20Z","timestamp":1702140740000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-023-02345-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,11]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2345"],"URL":"https:\/\/doi.org\/10.1186\/s12931-023-02345-1","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,11]]},"assertion":[{"value":"6 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the amended Declaration of Helsinki and the protocol was approved by the Institutional Review Board of each institution (No. 2020-0218). Informed consent was waived due to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"75"}}